PAQ Therapeutics is developing autophagosome-tethering compounds (ATTECs) to enhance the selective degradation of disease-causing entities, including proteins, through the body's natural autophagy process. The company focuses on genetic neurodegenerative disorders that currently lack effective treatment options, aiming to create targeted therapies that address these unmet medical needs.
Funding
$34M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic neurodegenerative disorders lack effective treatments. These disorders often involve the accumulation of disease-causing entities, such as proteins, that the body cannot efficiently clear. Current therapeutic options are limited in their ability to selectively target and degrade these entities.
Solution
PAQ Therapeutics is developing autophagosome-tethering compounds (ATTECs) that enhance the selective degradation of disease-causing entities through the body's natural autophagy process. ATTECs are small molecules designed to catalyze and selectively enhance the degradation of specific targets by tethering them to autophagosomes, cellular structures responsible for waste removal. This approach expands the ability to target and eliminate disease-causing entities beyond proteins, offering a potential new class of small molecule degradation therapies. PAQ's platform aims to identify and design novel therapies for serious diseases with limited or no treatment options, initially focusing on genetic neurodegenerative disorders.
Target Audience
The primary target audience includes patients suffering from genetic neurodegenerative disorders and the medical professionals who treat them.
Features
- Autophagosome-tethering compounds (ATTECs) that selectively degrade disease-causing entities.
- Small molecule approach allows for targeted degradation of proteins and non-protein targets.
- Platform to identify and design novel therapies for diseases with limited treatment options.
- Focus on genetic neurodegenerative disorders.
- Potential to expand the ATTEC platform to target additional disease-causing entities.